Generate Biomedicines (GENB) vs Zymeworks (ZYME)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Zymeworks is the larger company by market cap ($1.80 billion vs $1.70 billion), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | GENB | ZYME |
|---|---|---|
| Share price | $13.22 | $25.09 |
| Market cap | $1.70B | $1.80B |
| 1-day change | -2.58% | -5.43% |
| YTD return | — | +0.76% |
| 1-year return | — | +60.79% |
| 5-year return | — | +2.27% |
| Forward P/E | — | 28.77 |
| EPS (TTM) | $-2.44 | $-2.02 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $22.67 | $31.34 |
| 52-week low | $11.00 | $16.00 |
| Distance from 52-week high | -41.69% | -19.94% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +104.24% | +64.25% |
| Average volume | 1.04M | 687.87K |
| Shares outstanding | 128.35M | 71.20M |
| Employees | 312 | 231 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Generate Biomedicines
GENB stock →Generate Biomedicines, Inc., engaged in the field of generative biology by using machine learning for drug discovery and development through the programming of novel protein therapeutics in the United States. It uses protein-based modalities for drug development.
Health Care · Biotechnology: Pharmaceutical Preparations · 312 employees
About Zymeworks
ZYME stock →Zymeworks Inc., a biotechnology company, develops biotherapeutics for the treatment of cancer, inflammation, and autoimmune diseases. The company's platforms include Azymetric multispecific antibody platform; Drug Conjugate platform that includes a suite of proprietary cytotoxins comprising topoisomerase and microtubulin inhibiting toxins, stable linkers, and conjugation technologies; EFECT platform, which consists of a set of modifications to the Fc region of antibodies; and ProTECT, a tumor-specific immune co-stimulation platform.
Health Care · Biotechnology: Pharmaceutical Preparations · 231 employees
GENB vs ZYME FAQ
Which is bigger, Generate Biomedicines or Zymeworks?
Zymeworks (ZYME) is larger, with a market capitalization of $1.80B compared with $1.70B for Generate Biomedicines (GENB).
Are Generate Biomedicines and Zymeworks in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.